Estriol (E3) Test

Estriol is the quiet member of the estrogen family. Outside of pregnancy it barely registers, but during pregnancy it climbs dramatically and becomes the body's main estrogen, produced jointly by the fetus and placenta working as a single unit.

That makes E3 (estriol) one of the few hormones whose level reflects fetal and placental function together. It also shows up in postmenopausal vaginal hormone therapy and in research on multiple sclerosis, bone preservation, and recurrent urinary tract infections, where its weaker estrogen activity is the point, not a limitation.

What Estriol Actually Is

Estriol belongs to the estrogen family alongside estrone (E1) and estradiol (E2). Of the three, E3 is the weakest and shortest acting. It binds to estrogen receptors with much lower affinity than estradiol, and it does not convert back into the more potent estrogens. In effect, it is a one-way endpoint of the estrogen pathway.

In nonpregnant adults, circulating levels are low. During pregnancy, estriol accounts for a large share of the estrogen in your blood, produced by the fetoplacental unit (the fetus and placenta working together). It supports uterine growth, placental development, and the changes that prepare the body for labor.

Why It Matters in Pregnancy

Because the placenta and fetus produce estriol together, its level acts as a window onto how well that partnership is working. Research has used estriol, and the ratio between progesterone and estriol, to flag pregnancies at higher risk of preterm birth, fetal growth problems, and other adverse outcomes. Specific thresholds are still being refined, and authors note that hormone ratios may carry more information than any single hormone read in isolation.

Predicting Preterm Birth

A prospective study of 956 singleton pregnancies tracked salivary estriol weekly starting at 22 weeks. A single elevated reading was associated with a higher risk of spontaneous preterm labor and birth, in both low-risk and high-risk women. Two consecutive elevated readings narrowed the false-positive rate further. In women already showing signs of preterm labor, an elevated salivary E3 identified a meaningful share of those who went on to deliver within two weeks.

Fetal Compromise in High-Risk Pregnancies

In 321 high-risk pregnancies, including chronic hypertension, intrauterine growth restriction, and pre-eclampsia, low plasma unconjugated estriol in late pregnancy lined up with low Apgar scores and certain neonatal complications. The signal was strongest in chronic hypertension and growth restriction, with a similar pattern in moderate to severe pre-eclampsia.

Investigators were careful to frame estriol as a risk marker that works alongside other fetal and placental tests, not a standalone trigger for early delivery. Most perinatal deaths in their cohort came from acute intrapartum events that no hormone test could have anticipated.

Predicting Delivery Within Seven Days

A study of 585 asymptomatic singleton pregnancies at or beyond 30 weeks used a sensitive lab method to measure four steroids in plasma. The best combination, estriol-16-glucuronide plus 17-alpha-hydroxyprogesterone (a related steroid in the same pathway), produced an AUC of about 0.69 (a measure of how well a test separates two groups, where 1.0 is perfect). Sensitivity and specificity were in a range where a negative result strongly argued against delivery within a week, while a positive result needed clinical context.

In plain terms, when the combined test is negative, delivery within a week is very unlikely. A positive result is much less specific and has to be interpreted alongside the rest of the clinical picture.

Estriol Outside Pregnancy

In nonpregnant adults, estriol is mostly studied as a therapy rather than a routine marker. The strongest evidence is in postmenopausal women using vaginal estriol for genitourinary syndrome of menopause (the cluster of vaginal dryness, irritation, and urinary symptoms that follow the drop in estrogen).

Vaginal Symptoms and Recurrent UTIs

Multiple randomized trials and reviews show that vaginal estriol reliably improves vaginal dryness, pH, tissue maturation, and symptom scores. Ultra-low-dose formulations of 0.005 to 0.03 mg work about as well as conventional 0.5 mg doses with less systemic absorption. A randomized trial in postmenopausal women with genitourinary syndrome found that ultra-low-dose 0.005% estriol vaginal gel reduced recurrent urinary tract infections, likely by improving vaginal pH.

Safety in Breast Cancer Survivors

For postmenopausal women on aromatase inhibitors (drugs that block estrogen production in breast cancer treatment), the worry with any vaginal estrogen is whether it raises systemic estrogen levels enough to interfere with treatment. In trials of 0.005% estriol vaginal gel, serum estrone and estradiol stayed undetectable. Estriol showed small, transient rises that normalized within weeks. Investigators describe this as oncologically acceptable, with the caveat that larger long-term trials are still needed.

Bone and Multiple Sclerosis

In early menopausal women, 2 mg oral estriol combined with a progestin preserved lumbar spine bone density over 24 months, comparable to conjugated estrogen and better than vitamin D3 or calcium alone. In relapsing-remitting multiple sclerosis, a randomized phase 2 trial added 8 mg oral estriol to standard glatiramer acetate therapy and reported a lower annual relapse rate at 1 year compared with placebo, with similar serious adverse events and no clear increase in breast or uterine pathology. Reviewers describe immunomodulatory and possible neuroprotective effects and have called for larger trials.

How Estriol Compares to Related Tests

Estriol is one of three main estrogens. The others are estradiol (E2), the dominant estrogen during reproductive years, and estrone (E1), the dominant estrogen after menopause. They are not interchangeable. Measuring estradiol tells you about cyclical ovarian activity. Measuring estriol tells you about fetoplacental function during pregnancy or, in the menopausal context, gives a sense of estriol exposure from vaginal therapy.

In prenatal screening, unconjugated estriol is often co-ordered with alpha-fetoprotein and human chorionic gonadotropin as part of multi-marker screens for chromosomal conditions and adverse pregnancy outcomes. Each marker contributes a different piece of the picture, and estriol's role is to reflect the steroid output of the fetoplacental unit.

Tracking Your Trend

A single estriol reading is hard to interpret in isolation. In pregnancy, the hormone climbs steeply across the trimesters, and abrupt drops or unexpectedly low values matter more than any one number. The preterm-birth research that found an increased risk did so by tracking weekly salivary estriol over months, not from a single test.

For women using vaginal estriol therapy, the practical question is whether serum levels are staying within the postmenopausal range despite local treatment. A baseline before starting therapy and a repeat after 4 to 12 weeks gives you a real picture of systemic absorption. If you are using estriol-based hormone therapy long-term, retest at least once a year, and sooner if symptoms or dose change.

When Results Can Be Misleading

Several factors can distort a single estriol reading and lead to the wrong conclusion.

• Early pregnancy timing: estriol is generally not detectable in plasma until about week 9. A low or undetectable result before that is expected, not a warning sign.
• Specimen choice: serum unconjugated estriol appears more sensitive than urinary estriol for detecting fetal compromise. A normal urinary reading does not rule out problems that a serum test might catch.
• Acute stress and severe illness: major illness can increase the conversion of androgens to estrogens in fat and other tissues, shifting estrogen levels in ways that have nothing to do with the condition you may be testing for.
• Vaginal estriol therapy: ongoing local treatment causes small, transient rises in serum estriol that usually normalize within hours to days. Timing the blood draw too close to a dose can produce a misleading spike.

What an Unexpected Result Should Make You Do

If you are pregnant and your estriol comes back unexpectedly low for gestational age, that is a reason to involve an obstetrician familiar with high-risk pregnancy. The next steps typically include reconfirming gestational age, looking at companion markers like alpha-fetoprotein and human chorionic gonadotropin, and using fetal monitoring or ultrasound rather than acting on the hormone number alone.

If you are postmenopausal and using vaginal estriol therapy and your serum estriol comes back higher than expected, retest at a different time relative to your dose before changing anything. If the elevation persists, talk with your prescribing clinician about dose, formulation, and whether companion estradiol and estrone measurements are warranted, especially if you have a personal or family history of estrogen-sensitive cancer.

Outside of pregnancy and vaginal hormone therapy, an isolated estriol result rarely changes management on its own. The useful question is always what other tests, symptoms, and circumstances accompany it.